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Antibiotic sutures 
against surgical site 
infections
Markus Diener and colleagues 
(July 12, p 142)1 might believe that 
the study protocol and sample size 
account for the conﬂ icting ﬁ ndings 
in the PROUD trial1 (not showing 
a prophylactic effect of triclosan-
coated sutures against surgical site 
infection [SSI]) and for findings 
from smaller randomised controlled 
trials2–4 that show benefits for use 
in antibiotic sutures in prevention 
of SSI. However, the discrepancy 
might be more because of differ-
ences in baseline characteristics of 
participants.
Antimicrobial eﬀ ects of triclosan-
coated sutures seem to depend on 
the length of skin incision, extent of 
wound contamination at operation, 
and concurrent diseases amenable 
to infections, such as diabetes. In 
a single-centre randomised trial,2 
investigators reported triclosan-
coated sutures to be of slight 
beneﬁ t because they decreased the 
rate of SSIs after open colorectal 
surgery, but did not change infection 
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Ebola crisis: beliefs and 
behaviours warrant 
urgent attention
Why is this 25th outbreak of Ebola 
in Africa presenting an impending 
geopolitical crisis?1
This is the ﬁ rst recognised outbreak 
in the west Africa region; the 
communities are not familiar with 
Ebola virus. Health beliefs, cultural 
practices, and human behaviour 
have combined to fan the dispersal 
of the disease. The concerns of the 
west African people, the myths, 
and conspiracies need to be heard 
and understood before communities 
will sufficiently engage to reduce 
further spread.
Civil unrest is a feature of this 
humanitarian disaster; suspicion and 
aggression towards health workers 
is widespread.2 The US and British 
military are indeed best resourced 
to build field hospitals; but their 
arrival is being seen on the ground, 
by some, as an invasion. These fears 
need to be addressed.
The socioeconomic collapse of the 
worst affected countries, already 
causing food insecurity,3 could 
exacerbate the destructive effects 
of Ebola, and create violence. The 
delivery of effective infection control 
measures and health care will be 
challenging under the threat of 
regional conflict.4 
This humanitarian disaster will 
deepen in spite of committed eﬀ orts of 
governments, unless we can understand 
and address the human beliefs and 
behaviours fuelling this crisis.
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diseases. It will also enable quick 
follow-up trials of combinations of 
antivirals and new treatments that 
have already shown evidence of 
activity. A diﬀ erent type of RCT might 
also become an option once more 
than one drug has shown eﬃ  cacy—
even efficacy in animal models. 
Then, patients could ethically be 
randomised to one investigational 
drug or another. No-one would get 
only standard care.
We accept that RCTs can generate 
strong evidence in ordinary circum-
stances; not, however, in the midst of 
the worst Ebola epidemic in history. 
The urgent need is to establish 
whether new investigational drugs 
oﬀ er survival beneﬁ ts, and thus which, 
if any, should be recommended by 
WHO to save lives. We have innovative 
but proven trial designs for doing 
exactly that. We should be using them, 
rather than doggedly insisting on gold 
standards that were developed for 
diﬀ erent settings and purposes.
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